(Q45060355)

English

Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy

scientific article published in September 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

author name string

Jayaweera DT

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kolber MA

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Brill M

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Tanner T

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Campo R

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Rodriguez A

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Chu HM

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Garg V

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

364-370

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Directly observed therapy for the treatment of tuberculosis--evidence based dosage guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00236.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2004.00236.X

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45060355&oldid=2064348395"